• In August 2024,Bayer AG submitted a new drug application to the U.S. Food and Drug Administration for elinzanetant, targeting the treatment of moderate to severe vasomotor symptoms associated with menopause. This application represented a significant step in addressing women's health needs.

• In June 2023,Pfizer Inc. relaunched DUAVEE (conjugated estrogens/bazedoxifene), an estrogen,based hormone therapy for menopause, in the United States after a voluntary recall. The recall addressed a packaging issue, which did not affect the product’s efficacy or safety.

In this report, the Menopausal Hot Flashes Therapeutics Market has been segmented by Therapy, Formulation, Distribution Channel, and Geography.

Menopausal Hot Flashes Therapeutics Market, Segmentation by Therapy

The Menopausal Hot Flashes Therapeutics Market has been segmented by Therapy into Hormonal Therapy and Non-hormonal .

Hormonal Therapy
Hormonal therapy accounts for approximately 60% of the menopausal hot flashes therapeutics market. This treatment involves the administration of estrogen or a combination of estrogen and progestin to manage the symptoms of menopause, including hot flashes. Hormonal therapy has been the most widely prescribed treatment due to its efficacy in relieving menopausal symptoms. However, its use has declined in some regions due to concerns about side effects such as breast cancer and heart disease.

Non-hormonal Therapy
Non-hormonal therapies represent about 40% of the market. These treatments are gaining popularity among women who are unable or unwilling to take hormones. Selective serotonin reuptake inhibitors (SSRIs), gabapentin, and clonidine are commonly prescribed to manage hot flashes in non-hormonal therapy. These therapies are particularly beneficial for women with contraindications to hormonal treatment and have fewer side effects compared to hormonal options.

Menopausal Hot Flashes Therapeutics Market, Segmentation by Formulation

The Menopausal Hot Flashes Therapeutics Market has been segmented by Formulation into Oral Medications,Topical Formulations, Injectables, and Dietary Supplements.

Oral Medications
Oral medications represent the largest segment of the menopausal hot flashes therapeutics market, accounting for approximately 50%. These treatments include hormonal therapies, such as estrogen and progestin, as well as non-hormonal medications like SSRIs and gabapentin. Oral medications are preferred by many women due to their convenience, ease of use, and effectiveness in managing hot flashes and other menopausal symptoms.

Topical Formulations
Topical formulations make up about 20% of the market. These include creams, gels, and patches that deliver active ingredients directly to the skin. Topical estrogen therapies, such as estradiol gels and patches, are commonly used to alleviate hot flashes and vaginal dryness. These formulations offer an alternative for women who prefer not to take oral medications and may help reduce systemic side effects.

Injectables
Injectables account for approximately 15% of the market. This segment includes hormonal injections such as depot medroxyprogesterone and testosterone, as well as botulinum toxin injections. Injectables are typically prescribed for women with more severe menopausal symptoms or those who do not respond well to oral medications. The growing trend towards long-acting injectables is expected to drive growth in this segment.

Dietary Supplements
Dietary supplements represent about 15% of the market share. These include herbal and plant-based supplements like black cohosh, soy isoflavones, and vitamin E, which are used to alleviate hot flashes and improve overall well-being during menopause. While less regulated than prescription treatments, dietary supplements are gaining popularity due to their natural ingredients and fewer side effects.

Menopausal Hot Flashes Therapeutics Market, Segmentation by Distribution Channel

The Menopausal Hot Flashes Therapeutics Market has been segmented by Distribution Channel intoHospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Hospital Pharmacies
Hospital pharmacies represent the largest distribution channel in the menopausal hot flashes therapeutics market, accounting for approximately 45%. These pharmacies are typically located within healthcare facilities, where patients are prescribed hormonal and non-hormonal treatments as part of their menopausal care. Hospital pharmacies are critical for providing immediate access to prescription medications, often for women with more severe symptoms who require professional medical oversight.

Retail Pharmacies
Retail pharmacies make up around 35% of the market. These include physical stores such as pharmacy chains and independent drugstores. Retail pharmacies offer over-the-counter treatments, including dietary supplements and topical formulations, as well as prescription medications. Many women purchase hot flash therapeutics at retail pharmacies due to their convenience, accessibility, and ability to provide both hormonal and non-hormonal treatments.

Online Pharmacies
Online pharmacies account for approximately 20% of the market. The growth of e-commerce has led to an increase in the number of women purchasing menopausal hot flashes therapeutics through online platforms. These pharmacies offer the convenience of doorstep delivery and easy access to prescription and over-the-counter treatments. The rise in demand for discreet purchasing and home delivery services is driving the expansion of this distribution channel.

Menopausal Hot Flashes Therapeutics Market, Segmentation by Geography

In this report, the Menopausal Hot Flashes Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Menopausal Hot Flashes Therapeutics Market Share (%), by Geographical Region

North America
North America holds the largest share of the menopausal hot flashes therapeutics market, accounting for approximately 40%. The United States and Canada are the primary contributors in this region, with strong demand for hormonal and non-hormonal treatments in managing menopausal symptoms. The widespread availability of prescription medications, along with increased awareness of menopause-related issues, continues to drive market growth in North America.

Europe
Europe represents around 30% of the global market share. Leading countries such as Germany, the United Kingdom, and France are adopting more advanced menopausal therapies. The growing focus on women’s health and the increasing use of hormonal therapy in managing hot flashes contribute to the region's steady market growth. Additionally, regulatory frameworks in the European Union encourage the use of safe and effective menopausal treatments.

Asia Pacific
The Asia Pacific region accounts for about 20% of the market. The demand for menopausal therapeutics is growing in countries like China, India, and Japan, driven by rapid urbanization, changing lifestyles, and an increasing aging population. The rise in awareness about menopause and hormonal therapy in this region is expected to contribute to market expansion in the coming years.

Middle East and Africa
The Middle East and Africa (MEA) region represents approximately 5% of the market. Menopausal hot flashes therapeutics are gaining adoption in countries like the UAE and Saudi Arabia, driven by a focus on women’s health and healthcare advancements. Though the market share is small, the growing awareness of menopausal treatments and the increasing access to healthcare facilities in this region are expected to propel market growth.

Latin America
Latin America holds around 5% of the global menopausal hot flashes therapeutics market. Countries like Brazil and Mexico are experiencing growing demand for menopausal treatments as awareness of menopause increases. The shift towards more modern healthcare systems and the availability of non-hormonal alternatives are contributing to the steady growth of the market in this region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Menopausal Hot Flashes Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing menopausal population
• Growing awareness of menopause-related symptoms

• Advancements in treatment options - Advancements in treatment options are significantly driving the growth of the global menopausal hot flashes therapeutics market. Traditional hormone replacement therapies (HRT) are now being supplemented and, in some cases, replaced by non-hormonal therapies, selective estrogen receptor modulators (SERMs), and novel drug candidates with improved safety profiles. These innovations offer more targeted symptom relief while minimizing the risk of adverse effects, addressing the needs of women who cannot or prefer not to use hormone-based treatments.

  Ongoing research is also contributing to the development of personalized medicine approaches, allowing treatments to be tailored based on individual risk factors, genetics, and hormonal status. This evolution in therapeutic strategies is improving patient outcomes and expanding the treatment landscape. As awareness of these advanced options grows among healthcare providers and patients, the market is expected to experience sustained demand for safer, more effective hot flash management solutions.

Restraints:

• Side effects and risks of hormone replacement therapy
• Expensive treatment and procedures

• Lack of awareness in emerging regions - Lack of awareness in emerging regions remains a significant restraint in the global menopausal hot flashes therapeutics market. In many low- and middle-income countries, limited knowledge about menopause and its associated symptoms prevents women from seeking appropriate medical attention. Cultural stigmas, social taboos, and the underrepresentation of menopausal health in public health initiatives further contribute to undiagnosed and untreated cases.

  This gap in awareness results in low adoption of available therapeutic options, even when treatments are accessible. Healthcare providers in these regions may also lack specialized training or resources to address menopause-related conditions effectively. Without targeted education campaigns and stronger healthcare infrastructure, the full potential of innovative therapeutics for hot flashes remains underutilized, limiting market growth in these regions.

Opportunities:

• Development of non-hormonal treatment options
• Expanding healthcare infrastructure in emerging markets

• Rising demand for personalized medicine - The rising demand for personalized medicine offers strong opportunities in the global menopausal hot flashes therapeutics market. Women experience menopause in highly individualized ways, influenced by genetics, hormonal profiles, and lifestyle factors. Personalized treatment strategies, supported by genetic testing and biomarker-driven diagnostics, allow healthcare providers to tailor therapies that better manage symptoms while minimizing side effects, especially in patients at risk for hormone-sensitive conditions.

  Pharmaceutical companies are increasingly focusing on targeted drug development and customized treatment protocols that align with this growing preference for individualized care. As patient awareness increases and precision medicine technologies become more accessible, the market is expected to benefit from improved adherence, higher treatment satisfaction, and broader adoption of innovative therapies for menopausal hot flashes.

Key players in Global Menopausal Hot Flashes Therapeutics Market include,

• Allergan plc
• Bayer AG
• Hisamitsu Pharmaceutical Co.
• Novartis International AG
• Novo Nordisk
• Pfizer
• Teva Pharmaceutical Industries Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis